News FDA rejection scuppers AZ’s hopes of a COPD triple clash wit... The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by
Market Access Verona to take COPD hopeful into phase 3 Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.
News Europe: thumbs up for Roche's Hemlibra, Chiesi rare disease ... Drug has been approved in US since November
News EU regulators back Chiesi drug for rare inherited disease Decision paves way for licence to treat alpha-mannosidosis,
News Verona pushes on with COPD drug after £70m fundraiser UK biotech hopes RPL554 could be a disease modifying drug.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.